Results 51 to 60 of about 436,511 (214)

British National Formulary Guidance on prescribing in pregnancy: A descriptive cross‐sectional study

British Journal of Clinical Pharmacology, EarlyView.
Aim To assess how well pregnancy‐specific guidance within the British National Formulary supports healthcare professionals to facilitate safe and effective medication use. Methods We performed a manifest content analysis of the text of all pregnancy sections within British National Formulary drug monographs, with inductive and iterative coding.
Hannah Johnson, Cleodie Swire, Lakshiv Dhingra, Toqa El‐Nahhas, Michelle Essiam, Salma Muse, Maria Tonkova, Nazmin Begum, Joan Morris, Emma Baker   +9 more
wiley   +1 more source

Acceptability of the dengue vaccination among parents in urban poor communities of Quezon City, Philippines before and after vaccine suspension

BMC Research Notes, 2018
Objective The study aims to illustrate the acceptability of the dengue vaccine before and after the dengue vaccination suspension in urban poor communities in Quezon City, Philippines.
Ezra M. Valido, Ida Safitri Laksanawati, Adi Utarini   +2 more
doaj   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Development of Peptide Vaccines in Dengue [PDF]

Current Pharmaceutical Design, 2018
Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease.
Reginald, Kavita, Chan, Yanqi, Plebanski, Magdalena, Poh, Chit Laa   +3 more
openaire   +2 more sources

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV‐3 in a Controlled Human Infection Model

Clinical Pharmacology &Therapeutics, EarlyView.
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N. Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert   +8 more
wiley   +1 more source

Maltase 1 regulates DENV2 infection and life history in Aedes aegypti

Insect Science, EarlyView.
Our study employed CRISPR/Cas9 to generate a MAL1 knockout strain of Aedes aegypti, demonstrating that the absence of MAL1 significantly suppresses DENV2 replication in the midgut and impairs viral transmission. The mutation also altered life‐history (hatching/pupation/emerging rates and sex‐specific survival), identifying MAL1 as a novel target for ...
Man‐Jin Li, Jin Cheng, Ya‐Ming Zou, Quan‐Chao Liu, Ding Zhu, Ce‐Jie Lan   +5 more
wiley   +1 more source

Tick‐Borne Encephalitis (TBE) Vaccine in the National Immunisation Programme—For Whom, When and Where?

Acta Paediatrica, EarlyView.
ABSTRACT The incidence of Tick‐borne encephalitis (TBE) cases has increased. The presumed location of transmission of Tick‐borne encephalitis virus (TBEV) has been expanding increasingly in the western parts of Europe during the past decade. There has also been an increased incidence of surveillance‐reported TBE cases in southern Sweden and southern ...
H. H. Askling, D. Zavadska
wiley   +1 more source

Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?

Pathogens, 2020
The four serotypes of dengue virus are the most widespread causes of arboviral disease, currently placing half of the human population at risk of infection.
Lucas Wilken, Guus F. Rimmelzwaan
doaj   +1 more source

Pre-vaccination frequency of circulatory Tfh is associated with robust immune response to TV003 dengue vaccine.

PLoS Pathogens, 2022
It has been estimated that more than 390 million people are infected with Dengue virus every year; around 96 millions of these infections result in clinical pathologies.
Abdullah M Izmirly, Adam-Nicolas Pelletier, Jennifer Connors, Bhavani Taramangalam, Sawsan O Alturki, Emma A Gordon, Sana O Alturki, Joshua C Mell, Gokul Swaminathan, Vivin Karthik, Michele A Kutzler, Esper G Kallas, Rafick-Pierre Sekaly, Elias K Haddad   +13 more
doaj   +1 more source

Frayed Rope and Resilient Threads: Fijian Healthcare and the COVID‐19 Pandemic

Asia Pacific Viewpoint, EarlyView.
ABSTRACT In April 2021, Fiji faced international scrutiny due to ‘horrific’ hospital conditions, including staff and patients lacking food, non‐operational operating theatres, and critical shortages of beds, medicine, and equipment. After successfully avoiding a major outbreak in 2020, a sudden surge in COVID‐19 cases in 2021 overwhelmed the public ...
Sharon McLennan, Johanna Thomas‐Maude, Apisalome Movono, Akisi Ravono   +3 more
wiley   +1 more source